Immunogenicity and Safety of a Booster Dose of Live Attenuated Varicella Vaccine, and Immune Persistence of a Primary Dose for Children Aged 2 to 6 Years

Immunogenicity and Safety of a Booster Dose of Live Attenuated Varicella Vaccine, and Immune Persistence of a Primary Dose for Children Aged 2 to 6 Years

Aim: To evaluate the immunogenicity and safety of a booster dose of live attenuated varicella vaccine (VarV) manufactured by Sinovac (Dalian) Vaccine Technology Co. Ltd., and the immune persistence of a primary dose in 2- to 6-year-old children. Methods: A phase IV, open-label study was conducted in...

Full description

Bibliographic Details
Main Authors: Yukai Zhang, Lei Wang, Yanxia Wang, Wei Zhang, Ningning Jia, Zhiqiang Xie, Lili Huang, Wangyang You, Weifeng Lu, Erwei Li, Feilong Gao, Yuansheng Hu, Fanhong Meng, Shengli Xia
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Vaccines
Subjects:
live attenuated varicella vaccine
booster
immune persistence
immunogenicity
safety
Online Access:https://www.mdpi.com/2076-393X/10/5/660

Internet

https://www.mdpi.com/2076-393X/10/5/660

Similar Items